Screening for Prostate Cancer

医学 过度诊断 前列腺癌 前列腺癌筛查 前列腺 妇科 前列腺特异性抗原 癌症 内科学 肿瘤科 家族史
作者
US Preventive Services Task Force,David C. Grossman,Susan J. Curry,Douglas K Owens,Kirsten Bibbins‐Domingo,Aaron B. Caughey,Karina W. Davidson,Chyke A. Doubeni,Mark H. Ebell,John W. Epling,Alex R. Kemper,Alex H. Krist,Martha Kubik,C. Seth Landefeld,Carol M. Mangione,Michael Silverstein,Melissa A. Simon,Albert L. Siu,Chien‐Wen Tseng
出处
期刊:JAMA [American Medical Association]
卷期号:319 (18): 1901-1901 被引量:1432
标识
DOI:10.1001/jama.2018.3710
摘要

Importance: In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 13%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostate cancer have an increased risk of prostate cancer compared with other men. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer. The USPSTF also commissioned a review of existing decision analysis models and the overdiagnosis rate of PSA-based screening. The reviews also examined the benefits and harms of PSA-based screening in patient subpopulations at higher risk of prostate cancer, including older men, African American men, and men with a family history of prostate cancer. Findings: Adequate evidence from randomized clinical trials shows that PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened. Screening programs may also prevent approximately 3 cases of metastatic prostate cancer per 1000 men screened. Potential harms of screening include frequent false-positive results and psychological harms. Harms of prostate cancer treatment include erectile dysfunction, urinary incontinence, and bowel symptoms. About 1 in 5 men who undergo radical prostatectomy develop long-term urinary incontinence, and 2 in 3 men will experience long-term erectile dysfunction. Adequate evidence shows that the harms of screening in men older than 70 years are at least moderate and greater than in younger men because of increased risk of false-positive results, diagnostic harms from biopsies, and harms from treatment. The USPSTF concludes with moderate certainty that the net benefit of PSA-based screening for prostate cancer in men aged 55 to 69 years is small for some men. How each man weighs specific benefits and harms will determine whether the overall net benefit is small. The USPSTF concludes with moderate certainty that the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms. Conclusions and Recommendation: For men aged 55 to 69 years, the decision to undergo periodic PSA-based screening for prostate cancer should be an individual one and should include discussion of the potential benefits and harms of screening with their clinician. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes, and other health needs. Clinicians should not screen men who do not express a preference for screening. (C recommendation) The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older. (D recommendation).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
犹豫的完成签到,获得积分10
1秒前
魏同心发布了新的文献求助50
1秒前
昭昭完成签到,获得积分10
1秒前
2秒前
脑洞疼的应助被晕晕晕采纳,获得10
2秒前
3秒前
123完成签到,获得积分10
3秒前
好运常伴完成签到,获得积分10
3秒前
winner发布了新的文献求助10
4秒前
4秒前
222完成签到,获得积分10
4秒前
小元完成签到,获得积分10
4秒前
健壮的大有完成签到,获得积分10
5秒前
坚定青槐完成签到,获得积分10
5秒前
5秒前
5秒前
水星逃逸完成签到 ,获得积分10
6秒前
huahuahua发布了新的文献求助10
6秒前
超帅的香露完成签到,获得积分10
7秒前
7秒前
8秒前
马里奥发布了新的文献求助10
8秒前
康云完成签到 ,获得积分10
9秒前
Yannick发布了新的文献求助10
9秒前
10秒前
Mobius发布了新的文献求助10
10秒前
ranqiang发布了新的文献求助10
10秒前
天天快乐的应助被好运常伴采纳,获得10
11秒前
乔一完成签到 ,获得积分10
11秒前
五五帅完成签到,获得积分10
11秒前
连钧发布了新的文献求助10
12秒前
Otter发布了新的文献求助10
12秒前
氯化钠完成签到 ,获得积分10
12秒前
星辰大海的应助被joleisalau采纳,获得10
12秒前
12秒前
安吉拉学术记完成签到,获得积分10
13秒前
哈哈哈哈完成签到,获得积分10
13秒前
SciGPT的应助被zzzy采纳,获得10
14秒前
15秒前
齐一诺完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190887
求助须知:如何正确求助?哪些是违规求助? 9577962
关于积分的说明 21855797
捐赠科研通 7790040
什么是DOI,文献DOI怎么找? 3436475
关于科研通互助平台的介绍 2560312
邀请新用户注册赠送积分活动 2483216